Biopharma startup Poxel has appointed Khoso Baluch to its board of directors. Baluch will serve as an independent director. He is senior vice president & president European region at UCB, the global biopharmaceutical company. Poxel is backed by Edmond de Rothschild Investment Partners, InnoBio and Omnes Capital.
You are browsing the archive for Omnes Capital - peHUB.
French company EyeTechCare SA said it raised a $13 million third round of funding from private investor Bernard Chauvin as well as existing investors Omnes Capital (formerly Credit Agricole Private Equity) and the Lyon-based insurer SHAM. The company is developing medical devices for the ophthalmology market.
French company EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market has secured a third round of funding amounting to ten million euros ($13 million). Bernard Chauvin, a private investor, has taken an equity stake in the company alongside Omnes Capital (formerly Credit Agricole Private Equity) and the Lyon-based insurer SHAM.
Medisse has closed a Series B equity financing round for the clinical trial of its lead product FlexiSurge(R) Adhesion Barrier. New investor IIG has joined the existing investors, BioGeneration Ventures and Omnes Capital in the round. Medisse is active in resorbable implants for soft tissue applications, based on a patented flexible polymer platform.